# First Clinical Study of the Safety and Blood Levels of a Human Monoclonal Antibody (2217LS) Against Lyme Disease Bacteria in Healthy People

> **NCT04863287** · PHASE1 · COMPLETED · sponsor: **MassBiologics** · enrollment: 44 (actual)

## Conditions studied

- Lyme Disease

## Interventions

- **BIOLOGICAL:** 2217LS
- **OTHER:** 0.9% Sodium Chloride (NaCl)

## Key facts

- **NCT ID:** NCT04863287
- **Lead sponsor:** MassBiologics
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-11
- **Primary completion:** 2022-08-16
- **Final completion:** 2022-08-16
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2022-09-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04863287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04863287, "First Clinical Study of the Safety and Blood Levels of a Human Monoclonal Antibody (2217LS) Against Lyme Disease Bacteria in Healthy People". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04863287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*